INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS UMEC/VI IN PATIENTS WITH COPD: COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC

被引：1
|
作者：
Mursleen, S. [1 ]
Shah, D. [2 ]
Schroeder, M. [3 ]
Perdrizet, J. [2 ]
Ndirangu, K. [2 ]
Risebrough, N. [4 ]
Martin, A. [5 ]
机构：
[1] GSK, Mississauga, ON, Canada
[2] ICON Hlth Econ, New York, NY USA
[3] GSK, Brentford, England
[4] ICON, ICON Hlth Econ, Toronto, ON, Canada
[5] GSK, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2438
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRS44
引用
收藏
页码：S411 / S411
页数：1
相关论文
共 50 条
  • [41] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Afisi S. Ismaila
    Kieran J. Rothnie
    Robert P. Wood
    Victoria L. Banks
    Lucinda J. Camidge
    Alexandrosz Czira
    Chris Compton
    Raj Sharma
    Shannon N. Millard
    Olivia Massey
    David M. G. Halpin
    Respiratory Research, 24
  • [42] Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Afisi S. Ismaila
    Kieran J. Rothnie
    Robert P. Wood
    Victoria L. Banks
    Lucinda J. Camidge
    Alexandrosz Czira
    Chris Compton
    Raj Sharma
    Shannon N. Millard
    Olivia Massey
    David M. G. Halpin
    Respiratory Research, 25
  • [43] Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis"
    Marshall, Jonathan
    Sharma, Akanksha
    Darken, Patrick
    Ouwens, Mario
    Singh, Barinder
    Tansey-Dwyer, Deniz
    ADVANCES IN THERAPY, 2023, 40 (05) : 2549 - 2555
  • [44] Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis”
    Jonathan Marshall
    Akanksha Sharma
    Patrick Darken
    Mario Ouwens
    Barinder Singh
    Deniz Tansey-Dwyer
    Advances in Therapy, 2023, 40 : 2549 - 2555
  • [45] Real-World Disease Burden and Healthcare Resource Utilization Among Patients with COPD and Asthma Using Triple Therapy (FF/UMEC/VI) in the United States
    Igboekwe, Emmeline
    Verma, Sumit
    Paczkowski, Rosirene
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2024, 19 : 281 - 296
  • [46] A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis"
    Ismaila, Afisi S.
    Haeussler, Katrin
    Malmenas, Mia
    Sharma, Raj
    Compton, Chris
    Vogelmeier, Claus F.
    Han, MeiLan K.
    Halpin, David M. G.
    ADVANCES IN THERAPY, 2023, 40 (05) : 2556 - 2561
  • [47] A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
    Afisi S. Ismaila
    Katrin Haeussler
    Mia Malmenäs
    Raj Sharma
    Chris Compton
    Claus F. Vogelmeier
    MeiLan K. Han
    David M. G. Halpin
    Advances in Therapy, 2023, 40 : 2556 - 2561
  • [48] Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial
    Lee, Laurie A.
    Bailes, Zelie
    Barnes, Neil
    Boulet, Louis-Philippe
    Edwards, Dawn
    Fowler, Andrew
    Hanania, Nicola A.
    Kerstjens, Huib A. M.
    Kerwin, Edward
    Nathan, Robert
    Oppenheimer, John
    Papi, Alberto
    Pascoe, Steven
    Brusselle, Guy
    Peachey, Guy
    Sule, Neal
    Tabberer, Maggie
    Pavord, Ian D.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (01): : 69 - 84
  • [49] ARE PATIENTS WITH COPD MORE ADHERENT TO FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) COMPARED WITH MULTIPLE-INHALER TRIPLE THERAPY IN A REAL-WORLD UK PRIMARY CARE TREATED POPULATION?
    Halpin, D. M. G.
    Rothnie, K. J.
    Banks, V.
    Czira, A.
    Compton, C.
    Wood, R.
    Tritton, T.
    Massey, O.
    Wild, R.
    Snowise, N.
    Gubba, E.
    Sharma, R.
    Ismaila, A. S.
    Vogelmeier, C. F.
    THORAX, 2021, 76 : A20 - A21
  • [50] Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
    Ismaila, Afisi S.
    Risebrough, Nancy
    Schroeder, Melanie
    Shah, Dhvani
    Martin, Alan
    Goodall, Emma C.
    Ndirangu, Kerigo
    Criner, Gerard
    Dransfield, Mark
    Halpin, David M. G.
    Han, MeiLan K.
    Lomas, David A.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 : 2681 - 2695
12345